2024-09-01 - Analysis Report
##  MRK Stock Analysis Report

**Company Overview:** MRK, known as Merck & Co., Inc., is a global pharmaceutical company specializing in prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

1. **Rate of Return vs. S&P 500:**

   - MRK's cumulative return is 52.93%, lagging behind the S&P 500 (VOO) which has a return of 89.66%.
   - This puts MRK at a -19.31% difference compared to the S&P 500. 
   - The relative divergence of 42.44% suggests that MRK's performance is in the lower 42.44% percentile relative to the S&P 500's performance in its historical range. 

2. **Recent Price Movements:**

   - Closing price: 118.45
   - 5-day moving average: 117.22
   - 20-day moving average: 114.88
   - 60-day moving average: 122.73

   - The stock price is currently above the 5-day and 20-day moving averages, suggesting short-term bullish momentum. However, it is below the 60-day moving average, indicating potential for a longer-term downward trend.

3. **Technical Indicators:**

   - RSI: 81.9  -  High RSI indicates the stock is currently overbought.
   - PPO: 0.74  -  Positive PPO suggests potential for further price increases in the short term.
   - Delta_Previous_Relative_Divergence: -20.6  -  Negative delta indicates that the relative divergence is declining, implying a potential for a short-term price correction.

4. **Recent Earnings & Outlook:**

   | Date     | EPS   | Revenue       |
   |----------|-------|---------------|
   | 2024-08-05 | 2.15  | 16.11 B$     |
   | 2024-05-03 | 1.88  | 15.78 B$     |
   | 2023-11-03 | 1.87  | 15.96 B$     |
   | 2023-08-07 | -2.35 | 15.04 B$     |
   | 2024-08-05 | -2.35 | 15.04 B$     |

   - The most recent earnings report for 2024-08-05 showed an EPS of 2.15, exceeding analyst expectations. Revenue was also above the forecast. 
   - This indicates positive performance in the recent quarter, suggesting the company is performing well. 

**Overall Analysis:**

MRK's stock performance has lagged behind the S&P 500 in the long term. However, the recent earnings report signals positive momentum.  Technically, the stock appears overbought but is showing potential for further gains in the short term. The declining relative divergence suggests a possible correction in the near future. 

**Recommendation:**

While the recent earnings report provides a positive outlook, the overbought condition and the declining relative divergence suggest caution. Investors may want to wait for a slight pullback before considering a long position. This will allow for a better entry point with less risk. 
